Pediatrics

Pulmonary hemorrhage

Pulmonary Hemorrhage

PULMONARY HEMORRHAGE

Pulmonary hemorrhage (PH) is a serious condition in children, characterized by bleeding into the alveoli and airways of the lungs

Pulmonary haemorrhage is an acute bleeding from the lung, from the upper respiratory tract, the trachea, and the alveoli

Pulmonary hemorrhage (PH) in infants is a serious condition characterized by bleeding into the lungs, often presenting as fresh, bloody fluid from the endotracheal tube (ETT) or lower respiratory tract.

Defining Pulmonary Hemorrhage:

  • Massive Pulmonary Hemorrhage: Involves at least two lobes of the lungs.
  • Histological Definition: Presence of red blood cells (RBCs) within the alveolar spaces or interstitium of the lung tissue.

 

The onset of pulmonary hemorrhage is characterized by productive cough with blood (hemoptysis) and worsening of oxygenation leading to cyanosis.

Causes of Pulmonary Heamorrhage

Infectious:

  • Viral: Respiratory syncytial virus (RSV), influenza, parainfluenza
  • Bacterial: Mycoplasma pneumoniae, Chlamydia pneumoniae
  • Other: Adenovirus, rhinovirus

Non-infectious:

  • Idiopathic: Occurs without a known cause, often associated with Goodpasture’s syndrome, an autoimmune disease
  • Trauma: Chest trauma, blunt force injury
  • Vascular abnormalities: Pulmonary arteriovenous malformations, pulmonary hypertension
  • Coagulation disorders: Hemophilia, von Willebrand disease
  • Druginduced: Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs)

Risk Factors of Pulmonary Heamorrhage

Maternal Risk Factors:

  • Pregnancy-related complications:
    • Preeclampsia/Eclampsia (Pregnancy-induced hypertension)

    • Toxemia

    • Infection

  • Bleeding Disorders: Hemophilia, von Willebrand disease, etc.

  • Medications:

    • Anticonvulsants

    • Antitubercular drugs

    • Vitamin K antagonists

  • Lack of antenatal steroids: In preterm labor, this can weaken the infant’s lungs.

Infant Risk Factors:

  • Prematurity: Most common risk factor.
  • Low Birth Weight: Infants weighing less than 1000 grams are at increased risk.
  • Intrauterine Growth Restriction (IUGR): Limited growth in the womb.
  • Respiratory Problems:
    • Hypoxia (low oxygen levels)

    • Asphyxia (lack of oxygen)

    • Respiratory Distress Syndrome (RDS)

    • Meconium Aspiration

    • Pneumothorax (collapsed lung)

    • Surfactant Treatment

  • Sepsis: Bloodstream infection.

  • Mechanical Ventilation: Can irritate the lungs.

  • Patent Ductus Arteriosus (PDA), Heart Failure: Cardiovascular complications.

  • Disseminated Intravascular Coagulation (DIC), Coagulopathy: Bleeding disorders.

  • Multiple Births, Male Sex: Increased risk factors.

  • Hypothermia: Low body temperature.

  • Polycythemia: High red blood cell count.

  • Erythroblastosis Fetalis: Blood incompatibility between mother and fetus.

  • Extracorporeal Membrane Support: Used for severe respiratory distress.

  • Previous Use of Blood Products: Can increase the risk of bleeding.

  • Hypoplastic Lung Disease: Underdeveloped lungs.

Clinical Presentations of Pulmonary Heamorrhage

  • Bleeding from Airways: Oozing of blood from the nose, mouth, or ETT.
  • Secretions: Frothy pink tinged secretions followed by fresh bloody secretions.
  • Rapid Clinical Deterioration:
    • Increased work of breathing

    • Bradycardia (slow heart rate)

    • Apnea (cessation of breathing)

    • Cyanosis (blue discoloration of the skin)

    • Hypotension (low blood pressure)

    • Pallor (paleness)

    • Poor systemic perfusion (inadequate blood flow)

  • Signs of Infection or Congestive Heart Failure: Fever, cough, wheezing, edema, hepatosplenomegaly, murmur.

  • Lung Auscultation: Decreased breath sounds and crepitations (crackling sounds).

  • Respiratory distress: Difficulty breathing, rapid breathing, wheezing, coughing.

  • Hemoptysis: Coughing up blood, which can range from streaks of blood to frank blood.

  • Hypoxia: Low blood oxygen levels, leading to cyanosis (blue discoloration of the skin)

  • Fever: May be present if the PH is caused by an infection.

  • Chest pain: May be present if the PH is caused by trauma or a vascular abnormality.

  • Respiratory failure: Severe cases can lead to respiratory failure, requiring mechanical ventilation.

  • Anaemia: Continuous bleeding with decreased hematocrit (HCT) level resulting in anemia

Diagnosis of Pulmonary Hemorrhage

The common method of identifying the disease symptoms as well as the progression includes the following:

History and physical examination: Taking a detailed medical history and performing a physical examination to assess the severity of the condition.

Common Laboratory Investigations: These include:

  • Blood tests: Check for infection, coagulation disorders, Platelets count and other underlying conditions.
  • Complete Blood Count or CBC
  • Coagulation studies (Prothrombin time n-11-13.5 sec), thrombin time n- 14-19 sec, activated partial thromboplastin n- 30-40 sec)

Pulmonary function tests including elevated DLCO (diffusion capacity of the lungs for Carbon Monoxide), usually restrictive, is greater than an obstructive pattern with the low exhalation of Nitric Oxide.

Radiographic Imaging: The radiographic diagnosis includes –

  • Chest X-ray for detecting patchy alveolar opacification, Shows infiltrates and atelectasis (collapsed lung) consistent with pulmonary hemorrhage.
  • CT chest for detecting spreading of the disease in normal areas
  • Bronchoscopy: A procedure where a thin, flexible tube is inserted into the airways to visualize the lungs directly and obtain samples for testing.

Serologic tests are performed to find out the exact underlying disorders.

Echocardiography may also require if there is mitral stenosis.

Lung or renal biopsy is often done when a cause is undetectable or if the progression of the disease is very fast. Specimens usually show blood along with numerous siderophages and erythrocytes; lavage fluid characteristically remains hemorrhagic or becomes highly hemorrhagic just after consecutive sampling.

Management of Pulmonary Heamorrhage

Aims

  • To decrease and stop the bleeding in the lungs.
  • To identify the underlying cause.
  • To improve gaseous exchange.
  • To improve distress

Treatment for Pulmonary Hemorrhage depends on the underlying cause and severity. It may include:

  • Supportive care: Oxygen therapy, mechanical ventilation, and fluid management.
  • Antibiotics: For bacterial infections.
  • Antivirals: For viral infections.
  • Corticosteroids: To reduce inflammation.
  • Plasmapheresis: A procedure to remove antibodies from the blood, used in cases of autoimmune disorders like Goodpasture’s syndrome.
  • Surgery: May be necessary to repair vascular abnormalities or remove blood clots.

Initial Stabilization and Support:

Airway Management: Secure a patent airway and ensure adequate ventilation.

  • Intubation may be required to facilitate mechanical ventilation.
  • Suctioning should be performed gently to minimize airway trauma.

Oxygenation: Provide supplemental oxygen as needed to maintain adequate oxygen saturation levels.

Hemodynamic Support:

  • Volume Expansion: Correct hypovolemia with intravenous fluids. Colloids may be used to improve vascular volume. Colloids are intravenous solutions that contain large molecules that remain in the vascular space, increasing blood volume and improving hemodynamic stability, and include Albumin.
  • Inotropes: Administer medications (e.g., dopamine, dobutamine) to improve cardiac output and blood pressure if needed.
  • Inotropes are medications that increase the force of myocardial contraction, leading to improved cardiac output and blood pressure
  • Packed Red Blood Cells (PRBCs): Transfuse PRBCs to correct anemia and maintain adequate hematocrit.

Acidosis Correction:

  • Address underlying causes of acidosis, including hypovolemia, hypoxia, and low cardiac output.
  • If necessary, administer sodium bicarbonate intravenously.

Emergency Measures

  • Through or by suctioning the airway initially until the bleeding subsides.
  • By increasing oxygen support.
  • Mechanical ventilation should be given in massive pulmonary hemorrhage.

Continuous Management

  • Packed Red Blood Cells to correct blood volume and hematocrit levels. Through administering blood, this will correct hypovolemia, hypoxia and also correct low cardiac output.
  • Rescue Surfactant: Consider administering a single dose of surfactant after the infant is stabilized on mechanical ventilation. This is plausible because blood inhibits surfactant function, but more research is needed to confirm its benefit. Rescue surfactant by using a single dose of surfactant after the infant has been stabilized on the ventilator.
  • Endotracheal Epinephrine: Administering epinephrine via the endotracheal tube or nebulized epinephrine may be considered in some cases, but effectiveness is not well-established.

Pharmacology Management

  1. Hemocoagulase: Is a new treatment method discovered from a brazilian snake’s venom. It has a thromboplastin-like effect that coverts prothrombin to thrombin and fibrinogen to fibrin. Its measured in KU(Klobusitzky Units) and dose os 0.5KU every 4-6 hours until hemorrhage is stopped.
  2. Activated Recombinant Factor VIIa (rFVIIa): This drug works by activating the extrinsic pathway and binds to tissue factor which will eventually bind and seal sites with vascular injury. For effectiveness o this drug, platelets can be administered too. The dosage is 50mg/kg twice daily for 2 – 3 days.
  3. Low-molecular-weight Heparin: This drug is found to provide better patient outcome for neonatal pulmonary hemorrhage as it does improve the pulmonary function and coagulation function and reduce the incidence of getting complications.
  4. Diuretics and steroids can also be helpful.

Complications of Pulmonary Heamorrhage

Respiratory Complications:

  • Respiratory Distress: The accumulation of blood in the alveoli can lead to severe respiratory distress, characterized by tachypnea, retractions, and cyanosis.
  • Hypoxemia: Blood in the alveoli can impair gas exchange, resulting in low blood oxygen levels (hypoxemia).
  • Pneumothorax: The pressure from blood in the lungs can cause a pneumothorax (collapsed lung).
  • Atelectasis: Blood in the alveoli can collapse the lung tissue, leading to atelectasis.
  • Bronchospasm: Some infants may develop bronchospasm in response to the irritation caused by blood in the airways.
  • Acute Respiratory Distress Syndrome (ARDS): Severe pulmonary hemorrhage can lead to ARDS, a life-threatening condition characterized by diffuse lung inflammation and impaired gas exchange.

Circulatory Complications:

  • Hypovolemia: The loss of blood into the lungs can lead to hypovolemia (low blood volume), which can result in hypotension, shock, and organ dysfunction.
  • Cardiac Dysfunction: Severe hypovolemia can impair cardiac function, leading to decreased cardiac output and heart failure.
  • Cerebral Edema: Hypotension and hypoxemia can lead to cerebral edema (swelling of the brain), which can cause neurological complications.

Other Complications:

  • Anemia: Significant blood loss can lead to anemia, which can further compromise oxygen delivery to the tissues.
  • Infection: Blood in the lungs can provide a breeding ground for bacteria, increasing the risk of infection.
  • Neurological Damage: Severe hypoxemia or cerebral edema can cause long-term neurological damage.

Long-Term Complications:

  • Chronic Lung Disease: Repeated episodes of pulmonary hemorrhage or severe ARDS can lead to chronic lung disease.
  • Developmental Delays: Severe hypoxemia or neurological damage can lead to developmental delays.



Nursing care plan for a patient with Pulmonary Hemorrhage

Assessment

Nursing Diagnosis

Goals/Expected Outcomes

Interventions

Rationale

Evaluation

1. Child presents with hemoptysis (coughing up blood), tachypnea, and respiratory distress (nasal flaring, use of accessory muscles).

Ineffective Airway Clearance related to bleeding in the lungs as evidenced by hemoptysis and respiratory distress.

The child will maintain a clear airway with reduced respiratory distress and no further episodes of hemoptysis.

– Continuously monitor respiratory status, including respiratory rate, effort, and oxygen saturation.

– Position the child in a semi-Fowler’s or upright position to facilitate breathing and reduce aspiration risk.

– Administer humidified oxygen to maintain adequate oxygenation.

– Prepare for possible intubation or mechanical ventilation if respiratory status worsens.

Continuous monitoring helps detect changes in respiratory status and guide interventions.

Positioning promotes optimal lung expansion and airway clearance.

Humidified oxygen eases breathing and reduces the work of breathing.

Mechanical ventilation may be necessary in severe cases to maintain adequate oxygenation.

The child’s respiratory rate and effort normalize, oxygen saturation remains above 92%, and hemoptysis is reduced or absent.

2. Child exhibits pale skin, cold extremities, and decreased capillary refill time.

Ineffective Tissue Perfusion related to blood loss from pulmonary hemorrhage as evidenced by pallor, cold extremities, and delayed capillary refill.

The child will maintain adequate tissue perfusion as evidenced by normal capillary refill time, warm extremities, and stable vital signs.

– Monitor vital signs, including heart rate, blood pressure, and capillary refill time, every 15-30 minutes initially.

– Administer intravenous fluids or blood products as prescribed to maintain circulatory volume and improve perfusion.

– Monitor hemoglobin and hematocrit levels regularly.

– Assess for signs of hypovolemic shock and initiate emergency interventions if needed.

Frequent monitoring of vital signs is crucial to assess the child’s circulatory status.

Fluid and blood product administration help restore circulating volume and improve tissue perfusion.

Hemoglobin and hematocrit monitoring guide transfusion and fluid therapy decisions.

Early detection of shock allows for prompt life-saving interventions.

The child’s capillary refill time improves to less than 2 seconds, skin color and temperature normalize, and vital signs stabilize.

3. Child is at risk for further bleeding due to underlying conditions (e.g., coagulopathy, infection).

Risk for decreased tissue perfusion related to pulmonary hemorrhage and underlying conditions.

The child will experience no further episodes of bleeding as evidenced by stable hemoglobin levels and the absence of hemoptysis.

– Monitor coagulation profiles (PT, PTT, INR) and platelet count regularly.

– Administer anticoagulants or clotting factors as prescribed to manage underlying coagulopathy.

– Avoid invasive procedures and handle the child gently to minimize the risk of provoking further bleeding.

– Educate parents on signs of bleeding and the importance of minimizing the child’s activity.

Regular monitoring of coagulation profiles helps identify and address coagulopathies.

Anticoagulants or clotting factors correct underlying coagulation abnormalities.

Gentle handling and avoiding invasive procedures reduce the risk of inducing further bleeding.

Parental education ensures early recognition of bleeding and adherence to activity restrictions.

 

4. Child exhibits anxiety and restlessness due to difficulty breathing and fear of bleeding.

Anxiety related to respiratory distress and fear of bleeding as evidenced by restlessness and verbalization of fear.

The child will demonstrate reduced anxiety as evidenced by calm behavior and verbalization of feeling more relaxed.

– Provide a calm and reassuring presence to reduce the child’s anxiety.

– Use age-appropriate communication to explain procedures and care to the child and family.

– Encourage the presence of a parent or caregiver at the bedside to provide comfort and support.

– Administer prescribed anxiolytics if the child’s anxiety remains severe despite non-pharmacological measures.

A calm presence helps alleviate the child’s fear and anxiety.

Age-appropriate explanations foster understanding and cooperation.

Parental presence provides emotional support and reassurance.

Anxiolytics may be necessary to reduce severe anxiety and facilitate care.

The child appears more relaxed, with reduced restlessness and verbalizes feeling less anxious.

5. Child is at risk for infection due to potential aspiration and compromised lung function.

Risk for Infection related to aspiration of blood and compromised lung function.

The child will remain free from infection as evidenced by normal temperature and absence of signs of infection.

– Monitor for signs of infection, including fever, increased WBC count, and changes in respiratory status.

– Maintain strict aseptic technique during all procedures and interventions.

– Administer prophylactic antibiotics as prescribed to prevent infection.

– Educate parents on the importance of hand hygiene and infection prevention measures at home.

Early detection and treatment of infection are critical to preventing complications.

Aseptic technique minimizes the risk of introducing pathogens.

Prophylactic antibiotics may reduce the risk of secondary infections.

Parental education ensures adherence to infection prevention practices.

 

 

Pulmonary Hemorrhage Read More »

Meconium Aspiration Syndrome

Meconium Aspiration Syndrome

Meconium aspiration syndrome is troubled breathing (respiratory distress) in a newborn who has breathed (aspirated) a dark green, sterile fecal material called meconium into the lungs before or around the time of birth
  • Meconium is the earliest stool of a newborn. Occasionally, newborns pass meconium during labor or delivery, resulting in a meconium-stained amniotic fluid (MSAF).  Meconium is the first intestinal discharge from newborns, a viscous, dark-green substance composed of intestinal epithelial cells, lanugo, mucus, and intestinal secretions (eg, bile.
  • Meconium aspiration syndrome (MAS) is the inhalation of stained amniotic fluid, which can occur before, during, or immediately after birth.
Causes of Meconium Aspiration Syndrome
  • Placental insufficiency. When a mother has placental insufficiency, there is a lack of adequate blood flow to the baby, which can cause fetal distress, leading to the untimely passage of meconium.
  • Preeclampsia. When the placenta does not carry adequate oxygen and nutrition for the fetus due to maternal underperfusion such as preeclampsia, the placental villi show increased syncytial knots, villous agglutination, intervillous fibrin, and distal villous hypoplasia, while maternal vessels in the deciduadisclose atherosis or mural hypertrophy of the arterioles.
  • Maternal infection/chorioamnionitis. When the placental membranes are ruptured and amniotic fluid infection occurs, the placenta shows acute chorioamnionitis (as the maternal inflammatory response) and funisitis (as the fetal inflammatory response).
  • Fetal hypoxia. Fetal hypoxia leads to passage of meconium from neural stimulation of a maturing gastrointestinal system.
Clinical Features
  • Severe respiratory distress. Severe respiratory distress may be present; symptoms include cyanosis, end-expiratory grunting, nasal flaring, intercostal retractions, tachypnea, barrel chest due to the presence of air trapping, and in some cases, auscultated rales and rhonchi.
  • Staining of the fingernails. Yellow-green staining of fingernails, umbilical cord, and skin may be also observed.
  • Green urine. Green urine may be noted in newborns with MAS less than 24 hours after birth; meconium pigments can be absorbed by the lung and can be excreted in urine.
  • Meconium or dark green stains in the amniotic fluid
  • Tachypnea
  • Nasal flaring
  • Retractions
  • Cyanosis or desaturation
  • Rales
  • Rhonchi
  • Greenish yellow staining of the umbilical cord, nail beds, or skin. Meconium staining may be visible in the oropharynx and (on intubation) in the larynx and trachea.
  • Neonates with air trapping may have a barrel-shaped chest
  • Fetal distress
  • Signs of neonatal asphyxia
Pathophysiology

In utero, meconium passage results from neural stimulation of a maturing gastrointestinal (GI) tract, usually due to fetal hypoxic stress.

  • As the fetus approaches term, the GI tract matures, and vagal stimulation from the head or spinal cord compression may cause peristalsis and relaxation of the rectal sphincter, leading to meconium passage.
  • Meconium directly alters the amniotic fluid, reducing antibacterial activity and subsequently increasing the risk of perinatal bacterial infection.
  • In addition, meconium is irritating to fetal skin, thus increasing the incidence of erythema toxicum(common rash seen in full-term newborns)
  • However, the most severe complication of meconium passage in utero is perinatal aspiration of stained amniotic fluid (before, during, or immediately after birth)—ie, meconium aspiration syndrome (MAS).
  • Aspiration of meconium-stained amniotic fluid may occur if the fetus is in distress, leading to a gasping breathing pattern.
  • This aspiration induces hypoxia via four major pulmonary effects: airway obstruction, surfactant dysfunction, chemical pneumonitis, and pulmonary hypertension.
Diagnosis
  • Acid-base status. Measurement of arterial blood gas (ABG) pH, partial pressure of carbon dioxide (pCO2), and partial pressure of oxygen (pO2), as well as continuous monitoring of oxygenation by pulse oximetry, are necessary for appropriate management; the calculation of an oxygenation index (OI) can be helpful when considering advanced treatment modalities, such as extracorporeal membrane oxygenation (ECMO).
  • Serum electrolytes. Obtain sodium, potassium, and calcium concentrations at 24 hours of life in infants with MAS, because syndrome of inappropriate secretion of antidiuretic hormone (SIADH) and acute renal failure are frequent complications of perinatal stress.
  • Complete blood cell count. Hemoglobin and hematocrit levels must be sufficient to ensure adequate oxygen-carrying capacity; thrombocytopenia increases the risk for neonatal hemorrhage; neutropenia or neutrophilia with left shift of the differential may indicate perinatal bacterial infection.
  • Chest radiography. Chest radiography is essential in order to confirm the diagnosis of meconium aspiration syndrome (MAS) and determine the extent of the intrathoracic pathology; identify areas of atelectasis and air leak syndromes; ensure appropriate positioning of the endotracheal tube and umbilical catheters. Diagnosis is confirmed by chest x-ray showing hyperinflation with variable areas of atelectasis and flattening of the diaphragm
  • Echocardiography. Echocardiography is necessary to ensure normal cardiac structure and for assessment of cardiac function, as well as to determine the severity of pulmonary hypertension and right-to-left shunting.
  • Meconium passage and Respiratory distress

Differential Diagnosis
  • Aspiration Syndromes
  • Congenital Heart Disease with Pulmonary Hypertension
  • Pediatric Congenital Diaphragmatic Hernia
  • Pediatric Idiopathic Pulmonary Artery Hypertension
  • Pediatric Pneumonia
  • Pediatric Sepsis
  • Persistent Pulmonary Hypertension of the Newborn (PPHN)
  • Surfactant Deficiency
  • Transient Tachypnea of the Newborn
  • Transposition of the Great Arteries
Management of Meconium Aspiration Syndrome
  • Infants born with meconium aspiration syndrome should have routine neonatal care while monitoring for signs of distress according to the general neonatal resuscitation guidelines e.g. Suctioning to open up the airway
  • Pediatrics no longer recommend routine endotracheal suctioning for non-vigorous infants with meconium aspiration syndrome, Chest tube insertion under water seal drainage to treat atelectasis and pneumothorax in vigorous infants.
  • Newborns are admitted to the neonatal intensive care unit (NICU) if necessary.
  • Oxygen therapy: Supplemental oxygen is often needed in meconium aspiration syndrome with goal oxygen saturation > 90% to prevent tissue hypoxia and improve oxygenation.
  • Surfactant: The use of surfactant in meconium aspiration syndrome is not standard of care, however, as discussed above, surfactant inactivation has a role in the pathogenesis of meconium aspiration syndrome. Therefore surfactant may be helpful in some cases
  • Cardiac exam. In patients with meconium aspiration syndrome (MAS), a thorough cardiac examination and echocardiography are necessary to evaluate for congenital heart disease and persistent pulmonary hypertension of the newborn (PPHN).
  • Rooming-in. If the baby is vigorous (defined as having a normal respiratory effort and normal muscle tone), the baby may stay with the mother to receive the initial steps of newborn care; a bulb syringe can be used to gently clear secretions from the nose and mouth.
  • Placing in a radiant warmer. If the baby is not vigorous (defined as having a depressed respiratory effort or poor muscle tone), place the baby on a radiant warmer, clear the secretions with a bulb syringe, and proceed with the normal steps of newborn resuscitation (ie, warming, repositioning the head, drying, and stimulating).
  • Minimize handling. Minimal handling is essential because these infants are easily agitated; agitation can increase pulmonary hypertension and right-to-left shunting, leading to additional hypoxia and acidosis; sedation may be necessary to reduce agitation.
  • Insertion of umbilical artery catheter. An umbilical artery catheter should be inserted to monitor blood pH and blood gases without agitating the infant.
  • Respiratory care. Continue respiratory care includes oxygen therapy via hood or positive pressure, and it is crucial in maintaining adequate arterial oxygenation; mechanical ventilation is required by approximately 30% of infants with MAS; make concerted efforts to minimize the mean airway pressure and to use as short an inspiratory time as possible; oxygen saturation should be maintained at 90-95%.
  • Surfactant therapy. Surfactant therapy is commonly used to replace displaced or inactivated surfactant and as a detergent to remove meconium; although surfactant use does not appear to affect mortality rates, it may reduce the severity of disease, progression to extracorporeal membrane oxygenation (ECMO) utilization, and decrease the length of hospital stay.
  • IV fluids. Intravenous fluid therapy begins with adequate dextrose infusion to prevent hypoglycemia; intravenous fluids should be provided at mildly restricted rates (60-70 mL/kg/day).
  • Diet. Progressively add electrolytes, protein, lipids, and vitamins to ensure adequate nutrition and to prevent deficiencies of essential amino acids and essential fatty acids.
  • Antibiotics such as Ampicillin and Gentamicin to prevent or treat any infection
  • Systemic vasoconstrictors. These agents are used to prevent right-to-left shunting by raising systemic pressure above pulmonary pressure; systemic vasoconstrictors include dopamine, dobutamine, and epinephrine; dopamine is the most commonly used.
  • Pulmonary vasodilator. Inhaled nitric oxide is a pulmonary vasodilator that has a role in pulmonary hypertension and persistent pulmonary hypertension (PPHN)
  • Neuromuscular blocking agents. These agents are used for skeletal muscle paralysis to maximize ventilation by improving oxygenation and ventilation; they are also used to reduce barotrauma and minimize oxygen consumption.
  • Sedatives. These agents maximize the efficiency of mechanical ventilation, minimize oxygen consumption, and treat the discomfort of invasive therapies.
meconium aspiration syndrome treatment
Nursing Diagnosis
  • Hyperthermia related to inflammatory process/ hypermetabolic state as evidenced by an increase in body temperature, warm skin and tachycardia.
  • Fluid volume deficit related to failure of regulatory mechanism.
  • Ineffective tissue perfusion related to impaired transport of oxygen across alveolar and on capillary membrane.
  • Interrupted breastfeeding related to neonate’s present illness as evidenced by separation of mother to infant.
  • Risk for Impaired parent/neonates attachment related to neonates physical illness and hospitalization
Nursing Care Planning and Goals
  • Patient will maintain normal core temperature as evidenced by vital signs within normal limits and normal WBC level.
  • Patient will be able to maintain fluid volume at a functional level as evidenced by individually adequate urinary output with normal specific gravity, stable vital signs, moist mucous membranes, good skin turgor and prompt capillary refill and resolution of edema.
  • Patient will be able to maintain fluid volume at a functional level as evidenced by individually adequate urinary output with normal specific gravity, stable vital signs, moist mucous membranes, good skin turgor and prompt capillary refill and resolution of edema.
  • Patient will demonstrate increased perfusion as evidenced by warm and dry skin, strong peripheral pulses, normal vital signs, adequate urine output and absence of edema.
  • The mother will identify and demonstrate techniques to sustain lactation until breastfeeding is initiated.
  • The mother shall still be able to identify and demonstrate techniques to sustain lactation and identify techniques on how to provide the newborn with breast milk.
  • The mother will identify and demonstrate techniques to enhance behavioral organization of the neonate
  • After discharge, the parents will be able to have mutually satisfying interactions with their newborn.
Nursing Intervention
  • Reduce body temperature. Provide TSB to help lower down the temperature; ensure that all equipment used for the infant is sterile, scrupulously clean; do not share equipment with other infants to prevent the spread of pathogens, and administer antipyretics as ordered.
  • Improve fluid volume level. Monitor and record vital signs to note for alterations; provide oral care by moistening lips & skin care by providing daily bath; administer IV fluid replacement as ordered to replace fluid losses.
  • Increase tissue perfusion. Note quality and strength of peripheral pulses; assess respiratory rate, depth, and quality; assess skin for changes in color, temperature, and moisture; elevate affected extremities with edema once in a while to lower oxygen demand.
  • Improve frequency of breastfeeding. Demonstrate the use of manual piston-type breast pump.; review techniques for storage/use of expressed breast milk; provide privacy, calm surroundings when the mother breastfeeds; recommend for infant sucking on a regular basis, and encourage the mother to obtain adequate rest, maintain fluid and nutritional intake, and schedule breast pumping every 3 hours while awake.
  • Improve infant-parent relationship. Educate parents regarding child growth and development, addressing parental perceptions; involve parents in activities with the newborn that they can accomplish successfully, and recognize and provide positive feedback for nurturing and protective parenting behaviors.
Evaluation

Goals are met as evidenced by:

  • Patient maintained normal core temperature as evidenced by vital signs within normal limits and normal WBC level.
  • Patient was able to maintain fluid volume at a functional level as evidenced by individually adequate urinary output with normal specific gravity, stable vital signs, moist mucous membranes, good skin turgor and prompt capillary refill and resolution of edema.
  • Patient was able to maintain fluid volume at a functional level as evidenced by individually adequate urinary output with normal specific gravity, stable vital signs, moist mucous membranes, good skin turgor and prompt capillary refill and resolution of edema.
  • Patient demonstrated increased perfusion as evidenced by warm and dry skin, strong peripheral pulses, normal vital signs, adequate urine output and absence of edema.
  • The mother identified and demonstrated techniques to sustain lactation until breastfeeding is initiated.
  • The mother was able to identify and demonstrate techniques to sustain lactation and identify techniques on how to provide the newborn with breast milk.
  • The mother identified and demonstrated techniques to enhance behavioral organization of the neonate
  • After discharge, the parents were able to have a mutually satisfying interaction with their newborn.
Complications
  • Persistent pulmonary hypertension
  • Pneumothorax
  • Aspiration pneumonia
  • Brain damage due to lack of oxygen
  • Breathing difficulty that lasting for several days
  • Atelectasis (Collapsed lung)

Meconium Aspiration Syndrome Read More »

Broncho pulmonary dysplasia

Broncho pulmonary dysplasia

Broncho Pulmonary Dysplasia (BPD) is also known as 

  • Chronic lung disease of premature babies
  • Chronic lung disease of infancy
  • Neonatal chronic lung disease
  • Respiratory insufficiency
  • Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that affects newborns, most often those who are born prematurely and need oxygen therapy.
  • Bronchopulmonary dysplasia (BPD) is a persistent or prolonged respiratory disease characterized by irregular and scattered parenchymal densities or consolidated lungs.
  • In BPD the lungs and bronchi are damaged, causing tissue destruction (dysplasia) in the alveoli.
Causes of Broncho Pulmonary Dysplasia
  • Supplemental oxygen and mechanical ventilation in prematurity: When babies are born premature, their lungs often are not developed fully and they need help breathing. This breathing assistance usually comes from a mechanical ventilator or oxygen. In most cases, bronchopulmonary dysplasia develops after a premature baby receives this breathing assistance for a period of time because it can damage their already fragile lungs. 
  • Prolonged high oxygen delivery in premature infants causes necrotizing bronchiolitis and alveolar septal injury, with inflammation and scarring. This results in hypoxemia.
  • Vitamin A deficiency
  • Lung infections such as pneumonia
  • Congenital (present at birth) malformations of the lung
Pathophysiology
  • The pathogenesis of bronchopulmonary dysplasia remains complex and poorly understood.
  • Bronchopulmonary dysplasia results from various factors that can injure small airways and that can interfere with alveolarization/alveolar septation( Alveolarization represents a process during lung development that leads to the formation and maturation of the distal parts of the lung: the alveoli) , leading to alveolar simplification which means a reduction in the overall surface area for gas exchange.
  • Alveolar and lung vascular development are intimately related, and injury to one may impair development of the other. Damage to the lung during a critical stage of lung growth can result in clinically significant pulmonary dysfunction.
Pathogenesis

In the lungs, BPD causes damage to the current and developing alveoli. Additionally, the tiny blood vessels surrounding the alveoli may be affected, making the passage of blood through the lungs more difficult. The lower the number of working alveoli, the longer the infant may need to remain on a ventilator, which can cause further damage to the child’s lungs.

In the long run, increased pressure inside the blood vessels in the lungs and between the heart and lungs can cause pulmonary hypertension. In severe cases, heart failure can occur. Newborns who suffer from BPD may also experience trouble feeding, leading to delayed development.

Clinical Features

  • Tachypnea
  • Tachycardia
  • Increased respiratory effort (with retractions, nasal flaring, and grunting)
  • Frequent desaturations
  • Labored breathing
  • These infants are often extremely immature, have a very low birth weight, and have significant weight loss during the first 10 days of life.
  • Wheezing (a soft whistling sound as the baby breathes out)
  • The need for continued oxygen therapy after the gestational age of 36 weeks
  • Difficulty feeding
  • Repeated lung infections that may require hospitalization
  • There is bluish discoloration around the mouth or lips.
  • There are frequent alarms of the apnea monitor and/or pulse oximeter.

Diagnosis / Investigation

  • The diagnosis of BPD is based on the clinical evaluation, the degree of prematurity, and the need for oxygen after a certain age (2weeks).
  • Arterial blood gas (ABG) levels
  • Pulmonary function tests
  • Chest radiography
  • High-resolution chest computed tomography scanning
  • Chest magnetic resonance imaging
  • Echocardiography
Differential Diagnosis
  • Airway Injury
  • Nosocomial Infection
  • Patent Ductus Arteriosus (PDA)
  • Pediatric Hypertension
  • Pediatric Pneumonia
  • Pediatric Subglottic Stenosis Surgery
  • Pulmonary Atelectasis
  • Tracheomalacia

Management of Broncho Pulmonary Dysplasia

  • There is no specific cure for BPD, but treatment focuses on minimizing further lung damage and providing support for the infant’s lungs, allowing them to heal and grow. Newborns suffering from BPS are frequently treated in a hospital setting, where they can be continuously monitored
  • Surfactant replacement with oxygen supplementation
  • Continuous positive airway pressure (CPAP)
  • Mechanical ventilation
  • Treatment of the maternal inflammatory conditions and infections, such as chorioamnionitis
  • Diet
  • Maximization of protein, carbohydrates, fat, vitamins A
  • Early enteral feeding of small amounts (tube feeding), followed by slow, steady increases in volume: To optimize tolerance of feeds and nutritional support
Medical treatment
  • Diuretics: This class of drugs helps to decrease the amount of fluid in and around the alveoli. (eg, furosemide)
  • Bronchodilators: These medications help relax the muscles around the air passages, which makes breathing easier by widening the airway openings. They are usually given as an aerosol by a mask over the infant’s face and using a nebulizer or an inhaler with a spacer (eg, salbutamol, caffeine citrate, theophylline, ipratropium bromide)
  • Corticosteroids: These drugs reduce and/or prevent inflammation within the lungs. They help reduce swelling in the windpipe and decrease the amount of mucus that is produced. Like bronchodilators, they are also usually given as an aerosol with a mask with the use of a nebulizer or an inhaler. (eg, dexamethasone)
  • Vitamins (eg, vitamin A)
  • Keep the baby warm
  • Viral immunization: Children with BPD are at increased risk for respiratory tract infections especially respiratory syncytial virus (RSV)
  • Cardiac Medications: A few infants with BPD may require special medications that help relax the muscles around the blood vessels in the lung, allowing the blood to pass more freely and reduce the strain on the heart.
Complications
  • Difficulty feeding and reflux
  • Pulmonary hypertension
  • Hypercapnia
  • Increased bronchial secretions
  • Hyperinflation
  • Frequent lower respiratory infections
  • Delayed growth & development

Broncho pulmonary dysplasia Read More »

Respiratory distress syndrome

 Respiratory distress syndrome

  • Infant respiratory distress syndrome (IRDS), also called neonatal respiratory distress syndrome, (previously called hyaline membrane disease (HMD), is a syndrome in premature infants caused by developmental insufficiency of pulmonary surfactant production and structural immaturity in the lungs.
  • Respiratory distress syndrome (RDS) occurs in babies born early (premature) whose lungs are not fully developed. The earlier the infant is born, the more likely it is for them to have respiratory distress syndrome RDS and need extra oxygen and help breathing.
  • RDS is caused by the baby not having enough surfactant in the lungs. Surfactant is a liquid made in the lungs at about 26 weeks of pregnancy. As the fetus grows, the lungs make more surfactant.
  • Surfactant is a liquid that coats the inside of the lungs. It helps keep them open so that infants can breathe in air once they are born.

Causes of Respiratory Distress Syndrome

  • Lack or insufficient surfactant
  • It can also be a consequence of neonatal infection.
  • It can also result from a genetic problem with the production of surfactant associated proteins.

Risk Factors

  • Premature birth (before 37 weeks)
  • A sibling with respiratory distress syndrome
  • Multiple pregnancy (twins, triplets)
  • Impaired blood flow to the baby during delivery
  • Delivery by cesarean
  • Maternal diabetes
  • infection
  • Induction of labor before the baby is full-term
  • Multiple pregnancy (twins or more)
  • Cold stress. Baby with trouble of maintaining body temperature
  • Patent ductus arteriosus
  • Rapid labor
  • Prematurity

Pathophysiology

The lungs of infants with respiratory distress syndrome are developmentally deficient in a material called surfactant, which helps prevent collapse of the terminal air-spaces throughout the normal cycle of inhalation and exhalation.

This deficiency of surfactant is related to an inhibition from the insulin that is produced in the newborn especially in diabetic mothers. Deficient surfactant production causes un equal inflation of alveoli on inspiration and collapse of alveoli on end of expiration.

In this case their lungs inflate and therefore exert a great deal of effort to re-expand the alveoli with each breath with increasing exhaustion, they will be able to open the alveoli.

Inability to maintain lung expansion produces a wide spread of atelectasis. Progressive atelectasis with absence of alveolar stability will lead to increased pulmonary vascular resistance where as in normal cases it is supposed to decrease. Consequently there will be hypertension to the lung tissue a (pulmonary hypertension)decrease in effective pulmonary blood flow.

 

respiratory distress syndrome Pathophysiology

Phases of ARDS (Pathogenesis) 

ARDS has three phases—exudative, proliferative, and fibrotic. 

1.  Exudative Phase

In this phase, alveolar capillary endothelial cells and type I pneumocytes (alveolar epithelial cells) are injured, and tight alveolar barrier is damaged giving away the entry to fluid and macromolecules. The protein rich edema fluid accumulates in the interstitial and alveolar spaces. Pro-inflammatory cytokines are increased in this acute phase, leading to the recruitment of leukocytes (especially neutrophils) into the pulmonary space and alveoli. There is plasma proteins aggregation in air spaces with cellular debris and dysfunctional pulmonary surfactant to form hyaline membrane whorls of which Alveolar edema predominantly leads to  lung  diminished aeration. Collapse of large sections of dependent lung can contribute to decreased lung compliance. It causes intrapulmonary shunting and hypoxemia develop and the work of breathing increases, leading to dyspnea.

The exudative phase encompasses the first 7 days of illness after exposure to a precipitating ARDS risk factor. Tachypnea and increased work of breathing result frequently in respiratory fatigue and ultimately in respiratory failure.

2. Proliferative Phase

This phase of ARDS usually lasts from day 7 to day 21. Most patients recover rapidly and are liberated from mechanical ventilation during this phase. Despite this improvement, many patients still experience dyspnea, tachypnea, and hypoxemia. Histologically, the first signs of resolution are often evident in this phase, with the initiation of lung repair, the organization of alveolar exudates, and a shift from neutrophil- to lymphocyte- pulmonary infiltrates.

As part of the reparative process, type II pneumocytes proliferate along alveolar basement membranes. These specialized epithelial cells synthesize new pulmonary surfactant and differentiate into type I pneumocytes.

3. Fibrotic Phase

Most patients with ARDS recover lung function within 3–4 weeks, very few progresses into fibrotic phase that may require long-term support on mechanical ventilators and/or supplemental oxygen. There is extensive alveolar-duct and interstitial fibrosis. Marked disruption of acinar architecture leads to emphysema-like changes, with large bullae.

Intimal fibroproliferation in the pulmonary microcirculation causes progressive vascular occlusion and pulmonary hypertension. The physiologic consequences include an increased risk of pneumothorax, reductions in lung compliance, and increased pulmonary dead space.

Signs and Symptoms

  • Infant respiratory distress syndrome begins shortly after birth
  • Fast breathing
  • Fast heart rate
  • Chest wall retractions (recession)
  • Expiratory grunting
  • Nasal flaring
  • Cyanosis
  • Ventilatory failure (rising carbon dioxide concentrations in the blood) as condition progresses
  • Prolonged cessations of breathing (“apnea”).
  • Reduced urine output
Diagnosis/Investigation
  • Signs and symptoms
  • Chest x-ray
  • Pulse Oximetry
  • Echocardiography
  • CT scans
  • Arterial blood gas (ABG) test to assess the level of oxygen, CO2, and acids in blood
Differential Diagnosis
  • Acute Anemia
  • Aspiration Syndromes
  • Pediatric Gastroesophageal Reflux
  • Pediatric Hypoglycemia
  • Pediatric Pneumonia
  • Pediatric Polycythemia
  • Pneumomediastinum
  • Pneumothorax
  • Transient Tachypnea of the Newborn

Management / Treatment

  • Delivery and resuscitation: A neonatologist experienced in the resuscitation and care of premature infants should attend the deliveries of fetuses born at less than 28 weeks’ gestation.
  • Keep the child warm
  • Oxygen is given with a small amount of continuous positive airway pressure
  • I.V. fluids (N/S, D5%; (Neonatalyte i.e. D50%= 70mls, D5% = 310 & R/L=120ML) are administered to stabilize the blood sugar, blood salts, and blood pressure.
  • In severe cases an endotracheal tube is inserted into the trachea and intermittent breaths are given by a mechanical device.
  • A preparation of surfactant (e.g. survanta or beraksurf), is given through the breathing tube into the lungs.
  • Administer a glucocorticoid e.g. dexamethasone (0.15mg /kg/dose; max dose 4mg)
  • Give an antibiotic to prevent secondary bacterial infection
  • Respiratory monitoring, pulse rate, Bp, temperature, ECG monitoring.
  • Monitor conscious level
  • Reassure the mother
  • NG tube feeding
  • Vitamin k 0.5-1mgm I.M due to risk of intraventricular hemorrhage.
Prevention
  • Giving the mother glucocorticoids speeds the production of surfactant. Glucocorticoid treatment is recommended for women at risk for preterm delivery prior to 34 weeks of gestation (dose 12-40mg)
  • Early antenal care
  • Eat healthy diet rich in vitamins
  • Avoid smoking and alcohol during pregnancy
Complications
  • Metabolic disorders (acidosis, low blood sugar)
  • Patent ductus arteriosus
  • Low blood pressure
  • Chronic lung changes
  • Bleeding in the brain.

CASE SCENARIO

  1. A 1-day-old boy is brought to the intensive care unit from the nursery due to increased work of breathing. The patient was born at 31 weeks to a mother with a history of multiple preterm deliveries, polysubstance abuse and HIV. His temperature is 38°C (100.4°F), pulse is 215/min, respirations are 76/min, blood pressure is 60/41 mmHg, and oxygen saturation is 85% on room air. Physical exam shows tachypnea, nasal flaring, and subcostal retractions. Administration of supplemental oxygen and positive pressure ventilation improve the patient’s oxygen saturation to 95%. Blood glucose is 95 mg/dL. Chest x-ray and laboratory results are shown below:

     

Laboratory value  Result 
Blood Gases, Serum 
pH  7.23 
 PCO2  55 mmHg 
 PO2  30 mmHg 

Which of the following best describes the etiology of this infant’s disease process?

2.  Mike, a 55-year-old man, presents with shortness of breath, high fever, and cough. A chest x-ray was ordered and it showed a right lower lobe infiltrate, which is suggestive of pneumonia. He was then started on IV antibiotics but the following day Mike became hypoxic and hypotensive. Because his hypotension didn’t improve despite intubation, IV fluids, and vasopressors, he is diagnosed with septic shock. Next, a repeat x-ray detected newly-developed bilateral alveolar opacities, heart echography ruled out heart failure, and arterial blood gas analysis revealed a PF ratio of 109 milligrams Mercury.

3.   Dona, an infant delivered by cesarean section at 36 weeks’ gestational age, with an Apgar score of 9 at birth. A few hours after delivery, she develops tachypnea, chest wall retractions with nasal flaring, and tachycardia. Aside from increased work of breathing, her physical examination findings are normal. A chest x-ray was ordered and it showed diffuse reticulogranular ground glass appearance with air bronchograms.

Detailed Review.

All the above scenerio’s point to respiratory distress syndrome

But first, a bit of physiology.

Normally, when you breathe in, the air reaches the alveoli, which are made up of two types of pneumocytes.

First, type I pneumocytes are thin, and have a large surface area that that facilitate gas exchange.

More important for the exams are the type II pneumocytes, which are smaller, thicker and have the ability to proliferate in response to lung injury.

They are in charge of making a fluid called surfactant which contains various phospholipids. This lets it act like droplets of oil that coats the inside of the alveoli, decreasing surface tension, so if it’s missing, the alveoli will collapse.

These cells also act like stem cells, meaning they can give rise to type I cells and type II pneumocytes.

Ok, so acute respiratory distress syndrome, or ARDS, is characterized by rapid onset of widespread inflammation in the lungs which can lead to respiratory failure.

ARDS is not a primary disease, as it is usually triggered by conditions like sepsis, aspiration, trauma, and pancreatitis.

Now ARDS starts when these conditions cause alveolar damage, and a high yield fact is that the injury triggers the pneumocytes to secrete inflammatory cytokines like TNF-alpha and interleukin 1.

This subsequently leads to neutrophil recruitment, and they will release toxic mediators, like reactive oxygen species and proteases, which will damage the lungs even more.

You’ll need to know that the main site of injury is the alveolar-capillary membrane, which becomes more permeable, causing fluid to move into the alveoli resulting in pulmonary edema. This fluid can impair gas exchange, leading to hypoxemia.

Furthermore, the edema can also wash away the surfactant coating the alveoli to the point where it can’t reduce surface tension anymore, and as a result, the alveoli collapse.

And finally, dead cells and protein-rich fluid start to pile up in the alveolar space and, over time, it forms these waxy hyaline membranes which look like a layer of glassy material.

Individuals with ARDS present with serious symptoms and signs that require urgent investigation. The inflammation process and impaired gas exchange lead to fever, shortness of breath, tachypnea, chest pain, hypotension, hypoxia, and cyanosis. More often than not, ARDS will lead to shock due to hypotension.

The excess fluid in the lungs can cause a crackling sound called rales during auscultation, which is the sound of collapsed alveoli popping open with inspiration.

Keep in mind additional symptoms might provide clues to the underlying cause.

For example, epigastric abdominal pain radiating to the back along with a history of gallstones indicate acute pancreatitis. Diagnosis of ARDS is typically made when the individual presents all of the next four criteria, which you should definitely remember for your exams. First, the symptoms have to be “acute” meaning an onset of one week or less.

Second, and particularly high yield, a chest X-Ray or CT scan shows opacities or “white out” in both lungs, which is due to pulmonary edema.

The third is what’s called the PF ratio. It’s the partial pressure of oxygen in the arterial blood divided by the percent of oxygen in the inspired air, also called the fraction of inspired oxygen.

In ARDS, gas exchange is defective so the PF ratio is below 300 mmHg, and the lower this ratio gets, the more severe the condition.

Fourth, the respiratory distress must not be due to cardiac causes, like heart failure.

Often this is assessed by using an echocardiogram to look for evidence of heart failure, like an ejection fraction below 55% in systolic heart failure, and abnormal relaxation of the myocardium in diastolic heart failure.

Another clue is the pulmonary capillary wedge pressure, which is measured by inserting a catheter into a small pulmonary arterial branch.

In heart failure, this is elevated because more blood remains in the left side of the heart and it prevents pulmonary venous return.

The blood backs up into the pulmonary vessels, and the increase in pressure pushes fluid into the interstitial space of the lungs, resulting in edema.

In ARDS, the pressure is normal since the edema is caused by leaky capillaries instead of increased pressure.

Treatment of ARDS ultimately comes down to treating the condition that triggered it. However, the most important initial step is supportive care, like supplemental oxygen or mechanical ventilation.

A high yield fact to remember is that it’s vital to maintain positive end-expiratory pressure, which is where the pressure in the lungs is kept slightly above atmospheric pressure, even after exhalation, because this prevents the alveoli from collapsing. It’s also good to have low tidal volumes to prevent over-inflation of the damaged alveoli. Another important thing to watch out for is positive pressure ventilation can cause compression of pulmonary vessels which leads to pulmonary hypertension decreased pulmonary venous return.

This will reduce cardiac output and hypotension might worsen.

 Respiratory distress syndrome Read More »

Want this in PDF?

Copy the link

Send it to 0726113908 on WhatsApp

Prepare Shs. 5000 (1.3$)

And you will get the full PDF sent to you on WhatsApp.

Scroll to Top